Achaogen Announces FDA Advisory Committee Voted Unanimously in Favor of Plazomicin for Treatment of Adults with Complicated Urinary Tract Infections

SOUTH SAN FRANCISCO, Calif., May 02, 2018 (GLOBE NEWSWIRE) — Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee

Achaogen Stock Trading Halted Today

— FDA Advisory Committee to┬áReview Plazomicin for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI) and Bloodstream Infections (BSI) — SOUTH SAN FRANCISCO, Calif., May 02, 2018 (GLOBE NEWSWIRE) — Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing